AI reads MRI scans to predict liver cancer survival

NCT ID NCT07479264

Completed Knowledge-focused Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 169 patients with a type of liver cancer called intrahepatic cholangiocarcinoma. Researchers used MRI scans and machine learning to measure scar tissue and a protein linked to tumor growth. The goal was to see if these features could predict how long patients survive after surgery. No new treatments were tested—only existing medical images and tissue samples were analyzed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this approach could help doctors better predict survival and tailor follow-up care for liver cancer patients using standard MRI scans.
What could go wrong: This is an observational study, not a treatment trial. The findings are based on past data and need further validation before they can guide patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRAHEPATIC CHOLANGIOCARCINOMA (ICC)

Contacts and locations

Locations

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.